JP2011520976A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520976A5
JP2011520976A5 JP2011510669A JP2011510669A JP2011520976A5 JP 2011520976 A5 JP2011520976 A5 JP 2011520976A5 JP 2011510669 A JP2011510669 A JP 2011510669A JP 2011510669 A JP2011510669 A JP 2011510669A JP 2011520976 A5 JP2011520976 A5 JP 2011520976A5
Authority
JP
Japan
Prior art keywords
hydrate
melting point
melting
point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011510669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520976A (ja
JP6022158B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044622 external-priority patent/WO2009143211A2/en
Publication of JP2011520976A publication Critical patent/JP2011520976A/ja
Publication of JP2011520976A5 publication Critical patent/JP2011520976A5/ja
Application granted granted Critical
Publication of JP6022158B2 publication Critical patent/JP6022158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011510669A 2008-05-21 2009-05-20 2−フルオロ−N−メチル−4−[7−(キノリン−6−イル−メチル)−イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの塩及びそれを調製することに関する方法 Active JP6022158B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5499508P 2008-05-21 2008-05-21
US61/054,995 2008-05-21
PCT/US2009/044622 WO2009143211A2 (en) 2008-05-21 2009-05-20 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015040617A Division JP6105653B2 (ja) 2008-05-21 2015-03-02 2−フルオロ−N−メチル−4−[7−(キノリン−6−イル−メチル)−イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの塩及びそれを調製することに関する方法

Publications (3)

Publication Number Publication Date
JP2011520976A JP2011520976A (ja) 2011-07-21
JP2011520976A5 true JP2011520976A5 (https=) 2014-05-29
JP6022158B2 JP6022158B2 (ja) 2016-11-09

Family

ID=41058602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011510669A Active JP6022158B2 (ja) 2008-05-21 2009-05-20 2−フルオロ−N−メチル−4−[7−(キノリン−6−イル−メチル)−イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの塩及びそれを調製することに関する方法
JP2015040617A Active JP6105653B2 (ja) 2008-05-21 2015-03-02 2−フルオロ−N−メチル−4−[7−(キノリン−6−イル−メチル)−イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの塩及びそれを調製することに関する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015040617A Active JP6105653B2 (ja) 2008-05-21 2015-03-02 2−フルオロ−N−メチル−4−[7−(キノリン−6−イル−メチル)−イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの塩及びそれを調製することに関する方法

Country Status (30)

Country Link
US (7) US8420645B2 (https=)
EP (2) EP3287449A3 (https=)
JP (2) JP6022158B2 (https=)
KR (1) KR101706784B1 (https=)
CN (4) CN108586463A (https=)
AR (3) AR071873A1 (https=)
BR (1) BRPI0912882A2 (https=)
CA (1) CA2724742C (https=)
CL (1) CL2009001250A1 (https=)
CO (1) CO6300934A2 (https=)
CY (1) CY1119813T1 (https=)
DK (1) DK2300455T3 (https=)
EA (1) EA021364B1 (https=)
EC (1) ECSP10010685A (https=)
ES (1) ES2643363T3 (https=)
HK (1) HK1251568A1 (https=)
HR (1) HRP20171528T1 (https=)
HU (1) HUE034716T2 (https=)
IL (3) IL209229A (https=)
LT (1) LT2300455T (https=)
MA (1) MA32405B1 (https=)
MX (3) MX368802B (https=)
MY (3) MY199552A (https=)
NZ (2) NZ602791A (https=)
PL (1) PL2300455T3 (https=)
PT (1) PT2300455T (https=)
SI (1) SI2300455T1 (https=)
TW (1) TWI472529B (https=)
WO (1) WO2009143211A2 (https=)
ZA (1) ZA201008212B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
DE102013100596B4 (de) 2012-01-27 2023-09-07 Samsung Electronics Co. Ltd. Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
JP2015512425A (ja) * 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2016011658A1 (en) * 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10085993B2 (en) * 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對pd-l1之抗體分子及其用途
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Gabaa陽性アロステリックモジュレーター化合物、その作製の方法および使用
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021165818A1 (en) * 2020-02-17 2021-08-26 Novartis Ag Process and intermediates for the preparation of 2-fluoro-n-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2yl]benzamide
EP4159238A4 (en) * 2020-06-02 2024-08-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
WO2022063869A2 (en) * 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112480017A (zh) * 2020-11-13 2021-03-12 金仓(上海)医药生物科技有限公司 一种3-氨基-1,2,4-三嗪的制备方法
CN114621155A (zh) * 2020-12-14 2022-06-14 四川科伦药物研究院有限公司 一种制备卡马替尼的方法
CN114853762B (zh) * 2021-02-03 2026-03-06 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN119775203B (zh) * 2024-11-29 2025-11-14 河北科技大学 一种卡马替尼中间体6-(3,3-二乙氧基丙基)喹啉的合成方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) * 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4220450A (en) 1978-04-05 1980-09-02 Syva Company Chemically induced fluorescence immunoassay
US4209621A (en) * 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) * 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
DE3421029C2 (de) 1984-06-06 1986-04-24 Walter Steinhausen Mathis Verfahren und Vorrichtung zum trockenen Bedrucken eines Werkstückes unter Verwendung einer Heißprägefolie
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) * 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
DE60018037T2 (de) 1999-11-10 2006-01-12 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren
CN1390217A (zh) 1999-11-12 2003-01-08 神经原公司 二环和三环杂芳族化合物
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
EE200300437A (et) 2001-03-09 2004-02-16 Pfizer Products Inc. Triasolopüridiinid kui põletikuvastased ained
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
CA2448076A1 (en) 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
US20050096322A1 (en) * 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
WO2003080621A1 (en) 2002-03-19 2003-10-02 Merck & Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA05002123A (es) 2002-08-30 2005-06-06 Pfizer Prod Inc Nuevos procedimientos e intermedios para preparar triazolo-piridinas.
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
CA2529558A1 (en) 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
BRPI0412003A (pt) 2003-07-02 2006-08-15 Sugen Inc arilmetil triazol e imidazopirazinas como inibidores de c-met
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
EP1644362A2 (en) 2003-07-02 2006-04-12 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
EP1660500B1 (en) 2003-07-30 2007-12-12 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
AU2004284420A1 (en) 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
US7144889B2 (en) * 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
AU2005212096B2 (en) 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
EP1813613B1 (en) 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20090156617A1 (en) 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
US20080214562A1 (en) 2005-07-11 2008-09-04 Kristjan Gudmundsson Chemical Compounds
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Lck阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) * 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8481538B2 (en) * 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
CA2667453A1 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
CA2688823A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ

Similar Documents

Publication Publication Date Title
JP2011520976A5 (https=)
JP2012081521A5 (https=)
BRPI1009789A2 (pt) desacoplador.
ZA201107806B (en) Organisms for the production of 1,3-butanediol
JP2011168603A5 (https=)
EP2520575A4 (en) 1,3,4-oxadiazol-2-carboxamide CONNECTION
JP2011526809A5 (https=)
JP2013525942A5 (https=)
JP2009149903A5 (https=)
HUE042859T2 (hu) Korom, eljárás annak elõállítására, valamint annak alkalmazása
JP2011170856A5 (https=)
JP2015501646A5 (https=)
JP2013532130A5 (https=)
JP2011519825A5 (https=)
HUE044508T2 (hu) Eljárás alakos huzal elõállítására kiváló mechanikai tulajdonságokkal rendelkezõ, hidrogénridegedésnek ellenálló acélból
JP2012529342A5 (https=)
JP2011511794A5 (ja) 塩の製造のための方法
DE112010001147A5 (de) Erfassung der aktorposition
BRPI1008952A2 (pt) Composição herbicida.
JP2011217442A5 (https=)
JP2012044147A5 (https=)
JP2014507254A5 (https=)
JP2011170857A5 (https=)
BRPI1011203A2 (pt) Composição fungicida.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.